AUPH Archives - BioTuesdays

Developments

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced plans to present new data reinforcing the clinical significance of LUPKYNIS in the treatment of lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney...

October 11, 2024

Developments

Japan’s MHLW approves Aurinia’s LUPKYNIS (voclosporin) for lupus nephritis

Aurinia Pharmaceuticals (NASDAQ:AUPH), has announced that Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved voclosporin, a second-generation calcineurin inhibitor (CNI), in combination with...

September 25, 2024

Developments

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced that the first participant has been dosed in its Phase 1a study of AUR200, a differentiated, best-in-class potential therapy for autoimmune diseases targeting B-cell...

September 5, 2024

Executive Moves

Aurinia appoints Hepion’s Dr. Robert T. Foster to board

Aurinia Pharmaceuticals (NASDAQ:AUPH) appointed Dr. Robert T. Foster, CEO of Hepion Pharmaceuticals, to its board. “As the doctor who discovered voclosporin, and Aurinia’s founder, [Dr. Foster] has a wealth of...

September 21, 2023

Developments

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

The FDA approved Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. LUPKYNIS is...

January 25, 2021

Developments

FDA accepts Aurinia NDA for voclosporin; agrees to priority review

The FDA accepted for priority review Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) NDA for voclosporin for the treatment of lupus nephritis (LN). The NDA for voclosporin is based on the Phase 3 AURORA and Phase 2 AURA...

July 22, 2020

Developments

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...

December 4, 2019

Executive Moves

Aurinia Pharma names Peter Greenleaf as CEO; George Milne Jr. as chairman

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Peter Greenleaf as CEO, and George Milne Jr. as chairman of the board.

April 12, 2019

Feature

Lupus Foundation puzzled by negative reaction to Aurinia data

By Len Zehr As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of...

September 6, 2016

Tag - AUPH

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

Japan’s MHLW approves Aurinia’s LUPKYNIS (voclosporin) for lupus nephritis

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Aurinia appoints Hepion’s Dr. Robert T. Foster to board

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

FDA accepts Aurinia NDA for voclosporin; agrees to priority review

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aurinia Pharma names Peter Greenleaf as CEO; George Milne Jr. as chairman

Lupus Foundation puzzled by negative reaction to Aurinia data

General

More